Health Canada
Symbol of the Government of Canada
Consumer Product Safety

Incident Report

Subform I: General Information

1. Report Type.

New incident report

Incident Report Number: 2023-6559

2. Registrant Information.

Registrant Reference Number: FMC-55195

Registrant Name (Full Legal Name no abbreviations): FMC of Canada Limited

Address: 6755 Mississauga Road, Suite 204

City: Mississauga

Prov / State: Ontario

Country: Canada

Postal Code: L5N7Y2

3. Select the appropriate subform(s) for the incident.

Scientific Study

4. Date registrant was first informed of the incident.

5. Location of incident.

6. Date incident was first observed.

Product Description

7. a) Provide the active ingredient and, if available, the registration number and product name (include all tank mixes). If the product is not registered provide a submission number.


PMRA Registration No. 30890      PMRA Submission No.       EPA Registration No. 279-9613

Product Name: Cyazypyr Technical Insecticide

  • Active Ingredient(s)

7. b) Type of formulation.

Application Information

8. Product was applied?


9. Application Rate.

10. Site pesticide was applied to (select all that apply).

11. Provide any additional information regarding application (how it was applied, amount applied, the size of the area treated etc).

To be determined by Registrant

12. In your opinion, was the product used according to the label instructions?


Subform VII: Scientific Study

1. Study Reference


Date 01-MAY-23

2. a) Is an extension needed to translate the document?


3. Type of incident identified in the study

New health or environmental hazard

4. Describe the incident identified in the study (e.g. study demonstrates an increased risk to non-Hodgkin's Lymphoma after exposure to pesticide X)

FMC recently sponsored two studies: an Amphibian Metamorphosis Assay on the African Clawed Frog, and a Fish Short-Term Reproduction Assay on the Fathead Minnow; both conducted with Cyazypyr Technical, EPA Reg. No. 279-9613. Cyazypyr Technical contains the active ingredient cyantraniliprole. FMC considers these studies to be reportable information according to the Agency as memo dated July 15, 2011 with the subject: a Endocrine Disruption Screening Program (EDSP) Tier I Assays; Adverse Effects Reporting Obligations Clarification (FIFRA ASS 6(a)(2) and TSCA ASS8(e)).

5. a) Was the study discontinued before completion?


5. b) Provide the reason for discontinuation

6. If the study is ongoing, what is the expected completion date?

For Registrant use only

7. Provide supplemental information here